JANUET 50 MG850 MG Israël - anglais - Ministry of Health

januet 50 mg850 mg

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - tablets - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 850 mg - metformin - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

JANUVIA 25 MG Israël - anglais - Ministry of Health

januvia 25 mg

merck sharp & dohme (israel - 1996) company ltd, israel - sitagliptin as monohydrate phosphate - film coated tablets - sitagliptin as monohydrate phosphate 25 mg - sitagliptin - sitagliptin - januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus.important limitations of use:januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.januvia has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januvia.

JANUVIA 50 MG Israël - anglais - Ministry of Health

januvia 50 mg

merck sharp & dohme (israel - 1996) company ltd, israel - sitagliptin as monohydrate phosphate - film coated tablets - sitagliptin as monohydrate phosphate 50 mg - sitagliptin - sitagliptin - januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus.important limitations of use:januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.januvia has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januvia.

JANUVIA 100 MG Israël - anglais - Ministry of Health

januvia 100 mg

merck sharp & dohme (israel - 1996) company ltd, israel - sitagliptin as monohydrate phosphate - film coated tablets - sitagliptin as monohydrate phosphate 100 mg - sitagliptin - sitagliptin - januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus.important limitations of use:januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.januvia has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januvia.

CONCOR 10 MG Israël - anglais - Ministry of Health

concor 10 mg

merck serono ltd - bisoprolol fumarate - tablets - bisoprolol fumarate 10 mg - bisoprolol - bisoprolol - - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.- hypertension- coronary heart disease (angina pectoris)

ERBITUX 5 MGML Israël - anglais - Ministry of Health

erbitux 5 mgml

merck serono ltd - cetuximab - solution for infusion - cetuximab 5 mg/ml - cetuximab - cetuximab - erbitux® is indicated for the treatment of patients with epidermal growth factor receptor (egfr) - expressing, ras wild-type metastatic colorectal cancer• in combination with irinotecan-based chemotherapy• in first-line in combination with folfox• as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecanerbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck (scchn)• in combination with radiation therapy for locally advanced disease• in combination with platinum-based chemotherapy for recurrent and/or metastatic disease• as a single agent after failure of platinum-based chemotherapy for recurrent and/or metastatic disease

ZEPATIER Israël - anglais - Ministry of Health

zepatier

merck sharp & dohme israel ltd - elbasvir; grazoprevir - tablets - elbasvir 50 mg; grazoprevir 100 mg - elbasvir and grazoprevir - zepatier is indicated for the treatment of chronic hepatitis c (chc) genotypes 1 or 4 infection in adults

ZEPATIER Israël - anglais - Ministry of Health

zepatier

merck sharp & dohme (israel - 1996) company ltd, israel - elbasvir; grazoprevir - tablets - elbasvir 50 mg; grazoprevir 100 mg - elbasvir and grazoprevir - zepatier is indicated for the treatment of chronic hepatitis c (chc) genotypes 1 or 4 infection in adults

ZERBAXA 1 G0.5 G Israël - anglais - Ministry of Health

zerbaxa 1 g0.5 g

merck sharp & dohme israel ltd - ceftolozane as sulfate; tazobactam as sodium - powder for concentrate for solution for infusion - tazobactam as sodium 0.5 g; ceftolozane as sulfate 1 g - ceftolozane and enzyme inhibitor - zerbaxa is indicated for the treatment of the following infections in adults:-complicated intra abdominal infections;-acute pyelonephritis caused by pathogens resistant to other treatments as confirmed by urine culture-complicated urinary tract infections.-hospital-acquired pneumonia (hap), including ventilator-associated pneumonia (vap).consideration should be given to official guidance on the appropriate use of antibacterial agents

MAVENCLAD 10 MG TABLETS Israël - anglais - Ministry of Health

mavenclad 10 mg tablets

merck serono ltd - cladribine - tablets - cladribine 10 mg - cladribine - mavenclad 10mg tablets is indicated for the treatment of adult patients with highly active relapsing multiple sclerosis (ms) as defined by clinical or imaging features